Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients.

Giandomenico Roviello, Alberto Bottini, Daniele Generali

Open access · greenAbstract readLetterComment

In one paragraph

Article in European urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed, 2 pooled it

0.5field-weighted citation impact, top 29% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2 citations in OpenAlex.

Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis.Medical oncology (Northwood, London, England) · 2017
Pooled it
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials.Medicine · 2016
Pooled it

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Giandomenico RovielloDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Unit of Molecular Therapy and Pharmacogenomics, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy. Electronic address: giandomenicoroviello@gmail.com.

Alberto BottiniUnit of Molecular Therapy and Pharmacogenomics, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.

Daniele GeneraliUnit of Molecular Therapy and Pharmacogenomics, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Department of Medical, Surgery, and Health Sciences, University of Trieste, Piazza Ospitale, Trieste, Italy.

Istituti Ospitalieri di Cremona · ITUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Abiraterone AcetatePrednisoneAdrenal Cortex HormonesAgedHumansIncidenceMaleProstatic Neoplasms, Castration-ResistantAbiraterone AcetateAdrenal Cortex HormonesPrednisone

Identifiers

PMID27181830

DOI10.1016/j.eururo.2016.05.004

OpenAlexW2350204481

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.